Background: For the treatment of traumatic brain edema, an efficient modality has not yet emerged. There have been many studies to date which have reported the employment of low-frequency ultrasound for blood-brain barrier disruption (BBBD). However, the authors have observed that low-intensity ultrasound increases water permeability without cellular damage in cartilage cells. We have therefore attempted to observe the effects of applying this low-intensity ultrasound to an experimental animal model. Methods: A traumatic brain injury rat model was established according to the weight drop method developing the traumatic brain edema. The degree of BBBD was measured by the changes in the water content and spectrophotometric absorbance of Evans blue dye in the cerebrum after low-frequency ultrasound. Results: The cerebral water content levels showed that the BBBD gradually increased after impact and thereafter decreased after 6 h. After low-frequency ultrasound exposure, the values of water content and spectrophotometric absorbance of Evans blue dye were the lowest at 0 h, and were increased at 2 and 5 h of ultrasonic exposure (after impact). Conclusion: We suggest that traumatic brain edema in the rat model may be alleviated by low-frequency ultrasound, and low-frequency ultrasound might be proposed as a novel treatment modality for brain edema.

1.
Leitgeb J, Erb K, Mauritz W, Janciak I, Wilbacher I, Rusnak M, Australian Severe TBI Study Investigators: Severe traumatic brain injury in Austria. V. CT findings and surgical management. Wien Klin Wochenschr 2007;119:56–63.
2.
Artru F, Chacornac R, Deleuze R: Hyperbaric oxygenation for severe head injuries. Preliminary results of a controlled study. Eur Neurol 1976;14:310–318.
3.
Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C, Grimaud D, Leverve X: Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med 2009;35:471–479.
4.
Hutchison J, Ward R, Lacroix J, Hébert P, Skippen P, Barnes M, Meyer P, Morris K, Kirpalani H, Singh R, Dirks P, Bohn D, Moher D, HyP-HIT Investigators, Canadian Critical Care Trials Group: Hypothermia Pediatric Head Injury Trial: the value of a pretrial clinical evaluation phase. Dev Neurosci 2006;28:291–301.
5.
Jiang JY, Xu W, Li WP, Xu WH, Zhang J, Bao YH, Ying YH, Luo QZ: Efficacy of standard trauma craniectomy for refractory intracranial hypertension with severe traumatic brain injury: a multicenter, prospective, randomized controlled study. J Neurotrauma 2005;22:623–628.
6.
Schwab S, Steiner T, Aschoff A, Schwarz S, Steiner HH, Jansen O, Hacke W: Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke 1998;29:1888–1893.
7.
Enblad P, Nilsson P, Chambers I, Citerio G, Fiddes H, Howells T, Kiening K, Ragauskas A, Sahuquillo J, Yau YH, Contant C, Piper I, Brain IT Group: R3-survey of traumatic brain injury management in European Brain IT centres year 2001. Intensive Care Med 2004;30:1058–1065.
8.
Qiu W, Guo C, Shen H, Chen K, Wen L, Huang H, Ding M, Sun L, Jiang Q, Wang W: Effects of unilateral decompressive craniectomy on patients with unilateral acute post-traumatic brain swelling after severe traumatic brain injury. Crit Care 2009;13:R185.
9.
Morgalla MH, Will BE, Roser F, Tatagiba M: Do long-term results justify decompressive craniectomy after severe traumatic brain injury? J Neurosurg 2008;109:685–690.
10.
Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, Jolesz FA, Sheikov N: Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 2006;105:445–454.
11.
Ogura M, Paliwal S, Mitragotri S: Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev 2008;60:1218–1223.
12.
Park SR, Jang KW, Park SH, Cho HS, Jin CZ, Choi MJ, Chung SI, Min BH: The effect of sonication on simulated osteoarthritis. I. Effects of 1 MHz ultrasound on uptake of hyaluronan into the rabbit synovium. Ultrasound Med Biol 2005;31:1551–1558.
13.
Hollis PH, Zappulla RA, Spigelman MK, Feuer EJ, Holland JF, Malis LI: Effects of etoposide-induced blood-brain barrier disruption on brain water, intracranial pressure, and cerebral vasomotor tone. Exp Neurol 1988;99:428–439.
14.
Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin 2. Neurosurgery 1989;25:202–208.
15.
Reinhard M, Hetzel A, Krüger S, Kretzer S, Talazko J, Ziyeh S, Weber J, Els T: Blood-brain barrier disruption by low-frequency ultrasound. Stroke 2006;37:1546–1548.
16.
Mesiwala AH, Farrell L, Wenzel HJ, Silbergeld DL, Crum LA, Winn HR, Mourad PD: High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med Biol 2002;28:389–400.
17.
Yoshino S, Fukushima T, Hayashi S, Nonaka M, Ogawa K, Sasaki K, Umemura S: Effects of focused ultrasound sonodynamic treatment on the rat blood-brain barrier. Anticancer Res 2009;29:889–895.
18.
Feng Y, Tian Z, Wan M: Bioeffects of low-intensity ultrasound in vitro: apoptosis, protein profile alteration, and potential molecular mechanism. J Ultrasound Med 2010;29:963–974.
19.
Foda MA, Marmarou A: A new model of diffuse brain injury in rats. II. Morphological characterization. J Neurosurg 1994;80:301–313.
20.
Esen F, Erdem T, Aktan D, Kalayci R, Cakar N, Kaya M, Telci L: Effects of magnesium administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats. J Neurosurg Anesthesiol 2003;15:119–125.
21.
Cernak I, Vink R, Zapple DN, Cruz MI, Ahmed F, Chang T, Fricke ST, Faden AI: The pathobiology of moderate diffuse traumatic brain injury as identified using a new experimental model of injury in rats. Neurobiol Dis 2004;17:29–43.
22.
Go KG: The normal and pathological physiology of brain water. Adv Tech Stand Neurosurg 1997;23:47–142.
23.
Kempski O: Cerebral edema. Semin Nephrol 2001;21:303–307.
24.
Ayata C, Ropper AH: Ischaemic brain oedema. J Clin Neurosci 2002;9:113–124.
25.
Papadopoulos MC, Manley GT, Krishna S, Verkman AS: Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 2004;18:1291–1293.
26.
Meairs S, Alonso A: Ultrasound, microbubbles and the blood-brain barrier. Prog Biophys Mol Biol 2007;93:354–362.
27.
Venero JL, Machado A, Cano J: Importance of aquaporins in the physiopathology of brain edema. Curr Pharm Des 2004;10:2153–2161.
28.
Manley GT, Binder DK, Papadopoulos MC, Verkman AS: New insights into water transport and edema in the central nervous system from phenotype analysis of aquaporin-4 null mice. Neuroscience 2004;129:983–991.
29.
Taniguchi M, Yamashita T, Kumura E, Tamatani M, Kobayashi A, Yokawa T, Maruno M, Kato A, Ohnishi T, Kohmura E, Tohyama M, Yoshimine T: Induction of aquaporin-4 water channel mRNA after focal cerebral ischemia in rat. Brain Res Mol Brain Res 2002;78:131–137.
30.
Ke C, Poon WS, Ng HK, Pang JC, Chan Y: Heterogeneous responses of aquaporin-4 in oedema formation in a replicated severe traumatic brain injury model in rats. Neurosci Lett 2001;301:21–24.
31.
Kiening KL, van Landeghem FK, Schreiber S, Thomale UW, von Deimling A, Unterberg AW, Stover JF: Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neurosci Lett 2002;324:105–108.
32.
Sun MC, Honey CR, Berk C, Wong NL, Tsui JK: Regulation of aquaporin-4 in a traumatic brain injury model in rats. J Neurosurg 2003;98:565–569.
33.
Vykhodtseva N, McDannold N, Hynynen K: Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008;48:279–296.
34.
Mario B, Soeren N, Andreas E, Peter A: Cellular and molecular biology of the aquaporin water channels. Annu Rev Biochem 1999;68:425–458.
35.
Zderic V, Clark JI, Martin RW, Vaezy S: Ultrasound-enhanced transcorneal drug delivery. Cornea 2004;23:804–811.
36.
Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N: Local and reversible blood brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonication. Neuroimage 2005;24:12–20.
37.
McDannold N, Vykhodtseva N, Hynynen K: Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys Med Biol 2006;51:793–807.
38.
Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, Sedlaczek O, Koroshetz WJ, Hennerici MG: Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005;36:1441–1446.
39.
Chen Y, Constantini S, Trembovler V, Weinstock M, Shohami E: An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J Neurotrauma 1996;13:557–568.
40.
Dhillon HS, Carman HM, Zhang D, Scheff SW, Prasad MR: Severity of experimental brain injury on lactate and free fatty acid accumulation and Evans blue extravasation in the rat cortex and hippocampus. J Neurotrauma 1999;16:455–469.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.